While many AI companies focus on analyzing existing scientific literature, this approach faces a fundamental challenge: the reliability of the source material itself. “Up to 70% of experiments described in publications cannot be replicated,” notes Yochi Slonim, CEO of Anima Biotech. “You do it once and you publish it. You do it again, it doesn’t…